← Back to Search

Other

Combination Therapy for Pancreatic Cancer

Phase 2

Waitlist Available

Led By Erkut Borazanci, MD

Research Sponsored by HonorHealth Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Awards & highlights

Study Summary

This trial is testing a new combination of drugs to treat advanced pancreatic cancer. The drugs are nivolumab, albumin-bound paclitaxel, paricalcitol, cisplatin, and gemcitabine. The goal is to see if this combination is safe and effective.

Eligible Conditions

Metastatic Pancreatic Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Complete response rate

Secondary outcome measures

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Trial Design

1Treatment groups

Experimental Treatment

Group I: single armExperimental Treatment5 Interventions

open label using combination therapy

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Paricalcitol

2013

Completed Phase 4

~1730

Gemcitabine

2017

Completed Phase 3

~2070

Nivolumab

2014

Completed Phase 3

~4750

Cisplatin

2013

Completed Phase 3

~1940

Albumin-bound paclitaxel

2007

Completed Phase 3

~1160

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbIndustry Sponsor

2,638 Previous Clinical Trials

4,128,504 Total Patients Enrolled

HonorHealth Research InstituteLead Sponsor

25 Previous Clinical Trials

896 Total Patients Enrolled

Lustgarten FoundationOTHER

23 Previous Clinical Trials

5,363 Total Patients Enrolled

Media Library

Albumin-bound paclitaxel (Other) Clinical Trial Eligibility Overview. Trial Name: NCT02754726 — Phase 2

Pancreatic Cancer Research Study Groups: single arm

Pancreatic Cancer Clinical Trial 2023: Albumin-bound paclitaxel Highlights & Side Effects. Trial Name: NCT02754726 — Phase 2

Albumin-bound paclitaxel (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02754726 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the customary application of this intervention?

"This therapeutic approach is frequently employed to treat complete resection. It may also be used in the management of esophageal neoplasms malignant, prophylactic measures against central volume depletion, and previous adjuvant anthracycline-containing treatments."

Answered by AI

What potential adverse effects could patients experience when undergoing this procedure?

"Data collected during the Phase 2 of this trial suggests that it is relatively safe; thus, our team at Power gave a rating of two out of three. However, there is yet to be any evidence regarding its efficacy."

Answered by AI

How many participants are taking part in this clinical experiment?

"This clinical trial is no longer seeking applicants. It was first posted on April 1st, 2016 and the latest update occured February 15th, 2022. Fortunately for those interested in similar trials, there are 768 studies actively recruiting patients with adenocarcinoma and 2162 trials currently enrolling individuals to receive this treatment."

Answered by AI

Are there current opportunities for individuals to participate in this trial?

"Clinicaltrials.gov states that the search for participants of this trial has concluded, having first been posted on April 1st 2016 and last edited on February 15th 2022. Yet despite its closure, there are still 2930 studies actively searching for patients right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

2016. "Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02754726.